Publicacións en colaboración con investigadores/as de Complexo Hospitalario Universitario de Vigo (11)

2024

  1. Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study

    Movement Disorders Clinical Practice, Vol. 11, Núm. 7, pp. 830-849

2023

  1. AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability

    Brain, Behavior, and Immunity, Vol. 108, pp. 255-268

  2. Falls Predict Acute Hospitalization in Parkinson's Disease

    Journal of Parkinson's disease, Vol. 13, Núm. 1, pp. 105-124

2022

  1. Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease

    npj Parkinson's Disease, Vol. 8, Núm. 1

  2. Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson’s Disease Patients with Major Depression: An Open-Label Prospective Study

    Brain Sciences, Vol. 12, Núm. 11

2021

  1. Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR

    Advances in Therapy, Vol. 38, Núm. 10, pp. 5398-5411

  2. Predictors of clinically significant quality of life impairment in Parkinson’s disease

    npj Parkinson's Disease, Vol. 7, Núm. 1

2020

  1. Interaction between brain angiotensin and dopaminergic systems and Parkinson’s disease

    Genetics, Neurology, Behavior, and Diet in Parkinson’s Disease: The Neuroscience of Parkinson’s Disease, Volume 2 (Elsevier), pp. 463-477

  2. Maintenance treatment in metastatic colorectal cancer: in search of the best strategy

    Clinical and Translational Oncology, Vol. 22, Núm. 8, pp. 1205-1215

  3. Sustained Stable Disease with Capecitabine plus Bevacizumab in Metastatic Appendiceal Adenocarcinoma: A Case Report

    Case Reports in Oncology, Vol. 13, Núm. 1, pp. 69-75

2019

  1. Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report

    Frontiers in Oncology, Vol. 9